Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL164999 | 0.98 | CES2 (0.39) | CES2CES1HSD11B1HSD17B10NAAA | |
| SCHEMBL305181 | 0.98 | CES2 (0.34) | CES2CES1HSD11B1HSD17B10SMN1; SMN2 | |
| SCHEMBL165169 | 0.98 | CES2 (0.39) | CES2CES1HSD11B1HSD17B10NAAA | |
| SCHEMBL305183 | 0.98 | CES2 (0.34) | CES2CES1HSD11B1HSD17B10SMN1; SMN2 | |
| SCHEMBL164998 | 0.98 | CES2 (0.39) | CES2CES1HSD11B1HSD17B10NAAA | |
| SCHEMBL6520977 | 0.83 | NAAA (0.36) | CES2CES1HSD11B1HSD17B10SMN1; SMN2 | |
| SCHEMBL6520968 | 0.83 | NAAA (0.36) | CES2CES1HSD11B1HSD17B10SMN1; SMN2 | |
| SCHEMBL6514709 | 0.80 | SMN1; SMN2 (0.35) | CES2CES1HSD17B10SMN1; SMN2NAAA | |
| SCHEMBL6514696 | 0.80 | SMN1; SMN2 (0.35) | CES2CES1HSD17B10SMN1; SMN2NAAA | |
| SCHEMBL28712744 | 0.78 | CES2 (0.39) | CES2CES1HSD11B1NAAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160151322-A1 | METALLO-B-LACTAMASE INHIBITORS | MEIJI SEIKA KAISHA (JP) | 2016-06-02 | — | — | US | disclosed |
| US-9260375-B2 | Metallo-β-lactamase inhibitors | MEIJI SEIKA KAISHA, LTD. (JP) | 2016-02-16 | — | — | US | disclosed |
| US-9115079-B2 | NDM inhibitor | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2015-08-25 | — | — | US | disclosed |
| US-20140221330-A1 | NDM INHIBITOR | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2014-08-07 | — | — | US | disclosed |
| WO-2013015388-A1 | NDM INHIBITOR | Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 (JP) | 2013-01-31 | — | — | WO | disclosed |
| US-8093294-B2 | Bacterial infections; effective for recovering the activities of beta-lactam antibiotics; 2-ethyl-3-methylmaleic acid dimethyl ester; maleic acid derivatives and/or dihydrofuranyl derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2012-01-10 | — | — | US | disclosed |
| US-20080090825-A1 | Metallo-beta-lactamase inhibitors | MEIJI SEIKA KAISHA, LTD. (JP) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090825-A1 | Metallo-beta-lactamase inhibitors | ME1, MGAM, GAA | CES2 400/4885CES1 206/4885HSD11B1 384/4885 |
| US-20140221330-A1 | NDM INHIBITOR | MGAM, NQO1, NQO2 | CES2 557/4885CES1 481/4885HSD11B1 1299/4885 |
| US-20160151322-A1 | METALLO-B-LACTAMASE INHIBITORS | ME1, MGAM, MANBA | CES2 401/4885CES1 240/4885HSD11B1 419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.